CAV2 and nonpapillary renal cell carcinoma: As some of these genes (e.g., PTP4A3 and CAV2) have also been included in cancer gene signatures for predicting recurrence and prognosis[26,42], it is worth to postulate the effectiveness of a restricted panel of ccRCC tumor biomarker even if further validations and comparisons with clinical standards are required.